速递|被诺和诺德索赔60亿元,KBP Biosciences涉嫌“造假”

GLP1减重宝典
25 Feb

整理 | GLP1减重宝典内容团队早在 2023 年,诺和诺德就承诺向 KBP Biosciences支付高达 13 亿美元购买一种高血压和肾病药物,当时认为有潜力成为同类最佳。在这种药物去年年底惨败后,诺和诺德现在将责任归咎于该药物的原制造商涉嫌欺诈而索赔。根据 2 月 14 日新加坡法院的一项裁决,这家丹麦制药巨头计划向新加坡的 KBP Biosciences 及其创始人兼执行主席黄振华博士...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10